157 related articles for article (PubMed ID: 24908329)
1. Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients.
Kirn V; Shi R; Heublein S; Knabl J; Guenthner-Biller M; Andergassen U; Fridrich C; Malter W; Harder J; Friese K; Mayr D; Jeschke U
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1681-7. PubMed ID: 24908329
[TBL] [Abstract][Full Text] [Related]
2. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
[TBL] [Abstract][Full Text] [Related]
3. ESR1 promoter methylation in squamous cell cervical cancer.
Kirn V; Zaharieva I; Heublein S; Thangarajah F; Friese K; Mayr D; Jeschke U
Anticancer Res; 2014 Feb; 34(2):723-7. PubMed ID: 24511005
[TBL] [Abstract][Full Text] [Related]
4. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
5. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Zamagni C; Wirtz RM; De Iaco P; Rosati M; Veltrup E; Rosati F; Capizzi E; Cacciari N; Alboni C; Bernardi A; Massari F; Quercia S; D'Errico Grigioni A; Dietel M; Sehouli J; Denkert C; Martoni AA
Endocr Relat Cancer; 2009 Dec; 16(4):1241-9. PubMed ID: 19749010
[TBL] [Abstract][Full Text] [Related]
6. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.
Darb-Esfahani S; Wirtz RM; Sinn BV; Budczies J; Noske A; Weichert W; Faggad A; Scharff S; Sehouli J; Oskay-Ozcelik G; Zamagni C; De Iaco P; Martoni A; Dietel M; Denkert C
Endocr Relat Cancer; 2009 Dec; 16(4):1229-39. PubMed ID: 19675076
[TBL] [Abstract][Full Text] [Related]
8. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
9. ESR1-promoter-methylation status in primary breast cancer and its corresponding metastases.
Kirn V; Strake L; Thangarajah F; Richters L; Eischeid H; Koitzsch U; Odenthal M; Fries J
Clin Exp Metastasis; 2018 Oct; 35(7):707-712. PubMed ID: 30173322
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.
Zurita M; Lara PC; del Moral R; Torres B; Linares-Fernández JL; Arrabal SR; Martínez-Galán J; Oliver FJ; Ruiz de Almodóvar JM
BMC Cancer; 2010 May; 10():217. PubMed ID: 20487521
[TBL] [Abstract][Full Text] [Related]
11. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
Giannopoulou L; Mastoraki S; Buderath P; Strati A; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Gynecol Oncol; 2018 Aug; 150(2):355-360. PubMed ID: 29807696
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.
Buchholtz ML; Brüning A; Mylonas I; Jückstock J
Arch Gynecol Obstet; 2014 Jul; 290(1):149-54. PubMed ID: 24554348
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Changes of the ESR1 Gene in Breast Tissue of Healthy Women: A Missing Link with Breast Cancer Risk Factors?
Daraei A; Izadi P; Khorasani G; Nafissi N; Naghizadeh MM; Younosi N; Meysamie A; Mansoori Y; Bastami M; Tavakkoly-Bazzaz J
Genet Test Mol Biomarkers; 2017 Aug; 21(8):464-470. PubMed ID: 28708432
[TBL] [Abstract][Full Text] [Related]
15. Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
Vaclavikova R; Klajic J; Brynychova V; Elsnerova K; Alnaes GIG; Tost J; Kristensen VN; Rob L; Kodet R; Skapa P; Mrhalova M; Soucek P
Oncol Rep; 2019 Aug; 42(2):763-774. PubMed ID: 31173253
[TBL] [Abstract][Full Text] [Related]
16. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue.
Sinn BV; Darb-Esfahani S; Wirtz RM; Budczies J; Sehouli J; Chekerov R; Dietel M; Denkert C
Histopathology; 2011 Nov; 59(5):918-27. PubMed ID: 22092403
[TBL] [Abstract][Full Text] [Related]
18. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
Suzuki F; Akahira J; Miura I; Suzuki T; Ito K; Hayashi S; Sasano H; Yaegashi N
Cancer Sci; 2008 Dec; 99(12):2365-72. PubMed ID: 19032364
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract][Full Text] [Related]
20. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]